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Abstract
Aims/hypothesis The Anglo–Danish–Dutch study of inten-
sive treatment in people with screen-detected diabetes in
primary care (ADDITION) is a pragmatic randomised
controlled trial of the effectiveness of intensified multi-
factorial treatment on 5 year cardiovascular morbidity and
mortality rates in people with screen-detected type 2
diabetes in the Netherlands, UK and Denmark. This paper
describes the baseline characteristics of the study popula-
tion, their estimated risk of coronary heart disease and the
extent to which that risk is potentially modifiable.
Methods Stepwise screening strategies were performed
using risk questionnaires and routine general practice data
plus random blood glucose, HbA1c and fasting blood
glucose measurement. Diabetes was diagnosed using the
1999 World Health Organization criteria and estimated
10 year coronary heart disease risk was calculated using the
UK Prospective Diabetes Study risk engine.
Results Between April 2001 and December 2006, 3,057
people with screen-detected diabetes were recruited to
the study (mean age 59.7 years, 58% men) after a
stepwise screening programme involving 76,308 people
screened in 334 general practices in three countries.
Their median estimated 10 year risk of coronary heart
disease was 11% in women (interquartile range 7–16%)
and 21% (15–30%) in men. There were differences in
the distribution of risk factors by country, linked to
differences in approaches to screening and the extent to
which risk factors had already been detected and treated.
The mean HbA1c at recruitment was 7.0% (SD 1.6%). Of
the people recruited, 73% had a blood pressure ≥140/90
and of these 58% were not on antihypertensive medication.
Cholesterol levels were above 5.0 mmol/l in 70% of
participants, 91% of whom were not being treated with
lipid-lowering drugs.
Conclusions/interpretation People with type 2 diabetes
detected by screening and included in the ADDITION
study have a raised and potentially modifiable risk of CHD.
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Introduction
People with type 2 diabetes mellitus are at increased risk of
developing micro- and macrovascular complications and a
substantial reduction in life expectancy [1]. The onset of
this increased risk predates the point of clinical recognition
by several years [2] such that at diagnosis approximately
50% of people have evidence of diabetes-related compli-
cations [3–8]. Given the high prevalence of undiagnosed
diabetes [9–11] and the evidence that in people with
clinically diagnosed diabetes the risk of complications can
be effectively reduced by intensive treatment of hyper-
glycaemia [5–8]h y p e r t e n s i o n[ 12–14] and dyslipidaemia
[15, 16], screening and earlier initiation of such treatment
has been the subject of considerable debate [17–19]. How-
ever, critical uncertainties exist about the cost-effectiveness
and potential adverse consequences of screening, and given
this uncertainty, many international and national bodies have
concluded that population-based screening should not be
recommended without further evidence. A key uncertainty
factor in assessing the balance between the costs and benefits
of implementing policies for early detection of diabetes is the
magnitude of cardiovascular risk reduction following early
detection and intensive therapy [11]. Quantification of this
risk reduction is the goal of the Anglo–Danish–Dutch study
of intensive treatment in people with screen-detected diabetes
inprimarycare(ADDITION),arandomisedcontrolledtrialof
intensivemultifactorialtherapyinpeoplewithscreen-detected
diabetes in primary care. The aim of the analysis reported
in this paper is to describe the baseline characteristics of the
participants in the ADDITION study and in particular to
quantify their estimated risk of CHD using the risk prediction
equations developed in the UK Prospective Diabetes Study
(UKPDS). We also describe the extent to which the estimated
CHD risk in ADDITION study participants is potentially
modifiable.
Methods
Study design The ADDITION study is a pragmatic rando-
mised controlled trial of intensive multi-factorial treatment
compared with standard care in people with screen-detected
diabetes. The rationale and design of the study have been
reported previously [20]. Recruitment to the study com-
menced in April 2001 and was completed in December
2006 by which time 3,057 people with screen-detected
diabetes were recruited from four centres: one in Denmark,
two in UK (Cambridge and Leicester) and one in the
Netherlands. The primary endpoint for the 5 year follow-up
in December 2009 will be a composite cardiovascular
outcome comprised of cardiovascular mortality and mor-
bidity (myocardial infarction, non-fatal stroke) revascular-
isations and amputations.
Screening procedures In order to identify potential recruits
to this study, ADDITION undertook a programme of
population-based stepwise screening among people aged
40 to 69 years who were not known to have diabetes.
Individuals at high risk of diabetes were initially identified
using self-administered questionnaires in Denmark [21] and
the Netherlands [22, 23] or by automated search of comput-
erised general practice records in the UK [24]. Those at
high risk were asked to contact their physician (Denmark),
attend a community-based screening clinic (the Netherlands)
or were invited by letter to attend their local general practice
(Cambridge) or a screening clinic (Leicester). A sequential
process of screening using random glucose measurements
and HbA1c, followed by fasting glucose and OGTT as
diagnostic tests was undertaken. In the Leicester centre, all
people at high risk were invited directly for OGTT without
the intermediate testing steps. Participants were diagnosed
with diabetes according to the WHO criteria [25] using the
requirement for confirmatory tests on separate occasions.
Biochemical assessment Whole-blood glucose was ana-
lysed by near-patient testing using a glucose analyser
(HemoCue, Angelholm, Sweden). Calibration stability
was checked on a daily basis using control cuvettes. All
machines were registered with the HemoCue quality
assurance scheme and were externally calibrated at the
start of screening and subsequently recalibrated at regular
intervals. HbA1c was analysed in venous samples in five
local laboratories. The laboratories in Denmark (at Steno
Diabetes Centre, Gentofte, and Aarhus University Hospital,
Tage Hansensgade, Aarhus) and Cambridge (Department of
ClinicalBiochemistryatAddenbrookesHospital,Cambridge)
used ion-exchange high-performance liquid chromatography
on Tosoh machines (Tosoh Bioscience, Redditch, UK). The
laboratory in the Leicester centre (Leicester Royal Infirmary)
used the Biorad Variant II system (Bio-Rad Laboratories,
Hemel Hempstead, UK) and that in the Netherlands (SHL
Center for Diagnostic Support in Primary Care, Etten-Leur,
the Netherlands) used a Menarini 8140 machine (Menarini,
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laboratories demonstrated no noticeable systematic differ-
ences (<0.2%) in the HbA1c range of 3 to 11%. The
repeatability and reproducibility were within the range 0.1
to 0.5% in all laboratories. Fasting serum samples were
analysed in the same local laboratories for cholesterol,
HDL-cholesterol and triacylglycerol using standard enzy-
matic methods. LDL-cholesterol was calculated using the
Friedewald formula [26]. Plasma creatinine concentration
was analysed with kinetic colorimetric methods. Urinary
albumin was measured on spot urine by the immuno-
tubidimetric method and urinary creatinine by the colori-
metric method. The urinary albumin: creatinine ratio was
used to define microalbuminuria as ≥2.5 mg/mmol in
women and ≥3.5 mg/mmol in men.
Clinical measures Anthropometric measurements were
undertaken at baseline by trained staff following standard
operating procedures with height being measured to the
nearest 0.1 cm using a fixed rigid stadiometer and weight in
light indoor clothing measured to the nearest 0.1 kg with a
Seca scale. Body mass index (kg/m
2) was defined as weight
in kilograms divided by height in metres squared. Waist
circumference was measured at the mid-point between the
lower costal margin and the level of the anterior superior
iliac crest to the nearest 0.1 cm. Blood pressure was
measured using an Omron M4 blood pressure recorder
(Omron Healthcare, Milton Keynes, UK) with the partici-
pant in a sitting position.
Questionnaires Self-completed questionnaires were used to
assess baseline smoking status, alcohol consumption,
occupational status, ethnicity and self-reported medication.
Where needed, instruments were translated and back-
translated and the accuracy of translation verified using
established methods [27].
UKPDS risk engine The estimated absolute 10 year risk of
CHD was calculated using the previously published UKPDS
risk engine [28]. The risk was only estimated for those
participants with complete data on all the composite risk
factors required for the calculation, i.e. age, sex, ethnicity,
smoking status, HbA1c, systolic blood pressure, total
cholesterol and HDL-cholesterol, and duration of diabetes,
which for this population was by definition 0 years since all
the participants had screen-detected diabetes.
Ethics The study was approved by the local scientific ethics
committees in the specific countries and counties and was
conducted in accordance with the principles of the 1996
Helsinki Declaration. All participants provided informed
consent.
Data-handling and statistics The comparison of the baseline
characteristics of the study participants by group was
undertaken using Student’s t tests for continuously distributed
data and χ
2 tests for categorical variables. The Kruskal–
Wallis test was used where data were not normally distributed
or unequal variances were present. We used an imputation
method to estimate the impact of missing data for the UKPDS
risk score on our results. Missing continuous data such as
HbA1c, systolic blood pressure, total cholesterol and HDL-
cholesterol were imputed using the best-subset regressions
procedure [29]. Missing data for the categorical variables
(ethnicity and smoking status) were imputed using logistic
regression imputation. Where the predicted value was <0.5 it
was coded as 0 and where it was ≥0.5 it was coded as 1. No
sensitivity analyses of the imputation procedure were done.
All analyses were undertaken using Intercooled STATA 9.0
(StataCorp LP, College Station, TX, USA).
Results
Recruitment By the end of the screening phase of the
ADDITION study, 334 general practices (182 in Denmark,
49 in Cambridge, 24 in Leicester and 79 in the Netherlands)
had screened 76,308 people (28,031 in Denmark, 24,654
in Cambridge, 5,740 in Leicester and 17,883 in the
Netherlands). In total, 3,233 individuals with screen-detected
diabetes were identified and a total of 3,057 individuals
(1,533 in Denmark, 867 in Cambridge, 159 in Leicester and
498 in the Netherlands) were recruited to the ADDITION
study. There were no significant differences in the character-
istics of the 3,057 participants recruited to the trial compared
with the 176 patients with screen-detected diabetes who were
eligible but chose not to participate.
Baseline characteristics The baseline characteristics of the
participants recruited to the trial including the risk factors
for CHD are shown in Table 1. Across the centres signif-
icant differences were seen in the demographic character-
istics of the participants, largely by virtue of differences in
the underlying populations and the approach to screening.
The Leicester populationdiffered fromtheother three centres
by having the youngest population (mean age=57.2 years
comparedwith59.9yearsintheotherthreegroups,p<0.001),
the highest proportion of participants who were non-white
(41.3 compared with 3.9% in the other groups, p<0.001)
and the highest proportion of people who were not employed
(7.7 compared with 2.2% in the other centres, p<0.01). The
Danish population had the highest proportion of smokers
(35% compared with 26% in the Netherlands, 18% in
Cambridge and 16% in Leicester, p<0.001) and also had
the highest intake of alcohol units per week. The mean
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the other three centres (overall mean 7.3%, p<0.001).
Anti-hypertensive, lipid-lowering and antiplatelet therapy
In the total study population 73% of the participants had a
blood pressure greater than 140/90 mmHg and of these
58% had not been prescribed antihypertensive medication.
Therefore, overall 42% of the cohort was hypertensive but
not being treated. Even in the subpopulation of people
already receiving antihypertensive therapy (Table 2) there
was evident room for enhancement of blood pressure
lowering, since the mean blood pressure level in this
supposedly treated group was 151/86 mmHg. Indeed the
blood pressure levels in the population receiving therapy
were only marginally lower than those in the untreated
group. In this group, 67% of people did not meet the
treatment goal of a blood pressure of 140/90 showing the
potential for intensified therapy or for behavioural mod-
ifications to enhance treatment adherence. Similarly, 70%
of the cohort had a cholesterol level above 5.0 mmol/l.
More women (75%) than men (65%, p<0.001) were
hypercholesterolaemic. Nearly all of these people with high
cholesterol levels (91%) were not being treated with lipid-
lowering pharmaceuticals. Overall 64% of the participants
in the ADDITION trial had a total cholesterol level above
5 mmol/l at baseline but were not being treated. Among the
people who were receiving lipid-lowering therapy (Table 3),
there was evidence, as with blood pressure, that scope for
intensifying therapy or enhancing adherence existed, since
the mean cholesterol level in those receiving treatment was
4.9 mmol/l with a mean LDL-cholesterol of 2.8 mmol/l. Of
these individuals, 41% were not meeting the treatment goal
of a cholesterol level lower than 5 mmol/l. Of the total
population 15% had aspirin treatment at inclusion.
The two UK centres had the highest proportion of people
already on antihypertensive and lipid-lowering treatment at
baseline. In Cambridge and Leicester 49 and 58% of the
participants respectively were already on antihypertensive
therapy compared with 32% in Denmark and 37% in the
Netherlands (p<0.001). The mean systolic BP was lower in
Table 2 Baseline characteristics of participants with screen-detected
diabetes recruited to the ADDITION study (2001–2006), stratified by
antihypertensive therapy status
Already on
antihypertensive therapy
No antihypertensive
therapy
n (%) 1,159 (41) 1,644 (59)
Age (years) 60.9±6.5 59.0±7.0**
BMI (kg/m
2) 32.4±5.7 31.0±5.4**
Systolic BP
(mmHg)
151±22 152±23
Diastolic BP
(mmHg)
86±12 88±12*
Data shown are mean±SD, unless otherwise indicated
*p<0.05 vs participants on antihypertensive therapy
**p<0.001 vs participants on antihypertensive therapy
Table 1 Baseline characteristics of the 3,057 participants (1,771 men, 1,286 women) with screen-detected diabetes recruited to the ADDITION
study (2001–2006)
n with complete information Total Men Women
Age at diagnosis (years) 3,057 59.7±6.8 59.2±7.0 60.4±6.6**
Non-white (%) 2,941 5.3 5.0 5.8
Alcohol consumption (units/week) 2,675 4 (0–162) 8 (0–162) 2 (0–115)
Current smokers (%) 2,996 27 29 25**
Unemployed (%) 2,955 2.5 2.8 2.1
Already on antihypertensive treatment (%) 2,803 41 37 47**
Already on lipid-lowering treatment (%) 2,803 14 15 13*
HbA1c (%) 2,888 7.0±1.6 7.1±1.7 6.9±1.4*
Systolic BP (mmHg) 2,961 151±23 152±22 151±23
Diastolic BP (mmHg) 2,962 87±12 88±12 86±11**
BMI (kg/m
2) 2,960 31.6±5.6 31.0±5.0 32.3±6.2**
Waist (cm) 2,959 107±13 109±13 103±14**
Total cholesterol (mmol/l) 2,892 5.6±1.1 5.4±1.1 5.7±1.1**
Total triacylglycerol (mmol/l) 2,873 2.0±1.5 2.1±1.7 1.9±1.1**
HDL-cholesterol (mmol/l) 2,856 1.3±0.4 1.2±0.4 1.4±0.4**
LDL-cholesterol (mmol/l) 2,762 3.4±1.0 3.3±1.0 3.5±1.0**
Plasma creatinine (μmol/l) 2,830 84±18 90±17 75±15**
With microalbuminuria (%)
a 2,757 18.4 17.6 19.5
Data shown are mean±SD, median (range) or percentages
aUrinary albumin:creatinine ratio >2.5 (women), >3.5 (men)
*p<0.05 vs men
**p<0.001 vs men
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(151 mmHg) than among the Dutch (165 mmHg, p<0.001).
The mean diastolic blood pressure was significantly lower
in the Cambridge population than in the other populations
(83 mmHg compared with 89 mmHg in all other centres,
p<0.001). A similar pattern was seen for lipid-lowering
therapy, which was being prescribed to 26 and 21% of the
participants in Cambridge and Leicester respectively,
compared with 9% in Denmark and 15% in the Netherlands
(p<0.001). The mean total cholesterol concentration was
lowest in the Cambridge population compared with the
other centres (5.3 mmol/l vs 5.6 mmol/l in all other centres,
p<0.001).
CHD risk Table 4 shows the estimated absolute 10 year
CHD risk by age-group and sex. In the whole group, the
median 10 year risk was 16% (interquartile range 10–25%).
The estimated risk for CHD was higher for men (median
value=21%; interquartile range: 15–30) than for women
(11%; 7–16; p<0.001), and the oldest age group had a
significant higher risk than the younger groups (p<0.001).
We also observed minor differences in estimated risk
between countries, with the Dutch population having the
highest risk of developing CHD in the older age groups
(p<0.001). These high levels of estimated risk, together with
the high mean level of baseline HbA1c plus the untreated
hyperlipidaemia and hypertension, provide clear justification
for examining the impact of intensified multifactorial
therapy on this potentially modifiable risk.
Missing data As the UKPDS CHD risk score uses multiple
factors, it is susceptible to missing data since all variables
must be present for each individual for risk to be calculated.
A full dataset was available for 83% of the total population.
However, we investigated the effect of missing data on the
overall median CHD risk by imputing missing variables in
the remaining 17% of the population. As the results in
Table 4 demonstrate, the median CHD risk estimates were
unchanged when we included the values calculated using
imputation. This suggests that the results are not biased by
any specific characteristics of the individuals for whom
some data were missing.
Discussion
This analysis of the baseline data from the recruited
participants in the multi-national ADDITION trial demon-
strates that stepwise screening for diabetes in general
practice identifies people with type 2 diabetes whose
estimated 10 year CHD risk is high. In addition to their
untreated hyperglycaemia, the majority of the people with
demonstrable hypertension or hypercholesterolaemia were
not receiving treatment or were not being treated sufficient-
ly at baseline, suggesting that the elevated risk may be
modifiable through intensified lifestyle and pharmacologi-
cal therapy. In this trial, participants were randomised at the
general practice level to standard care or an intensified
approach geared to reducing cardiovascular risk. The 5 year
follow-up of the trial participants in 2009 will show
Table 4 Median estimated 10 year absolute CHD risk calculated from the UKPDS risk engine at baseline in the ADDITION study participants
(2001–2006), stratified by age and sex
Age group n Men Women Total Total including imputed values
a
40–49 years 216 12 (8–15) 5 (3–7) 9 (5–14) 9 (6–13)
50–59 years 930 18 (13–24) 8 (6–11) 14 (9–20) 14 (9–20)
60–69 years 1,398 26 (19–34) 13 (10–18) 19 (13–28) 19 (13–28)
Total population 2,544 21 (15–30) 11 (7–16) 16 (10–25) 16 (10–24)
Data are % (interquartile range), unless otherwise indicated. UKPDS risk can only be estimated in cases with complete data for all included
variables
aImputed values used when data were missing
Table 3 Baseline characteristics of participants with screen-detected
diabetes recruited to the ADDITION study (2001–2006), stratified by
lipid-lowering therapy status
Already on lipid-
lowering therapy
No lipid-lowering
therapy
n (%) 405 (14) 2,398 (86)
Age (years) 61.4±6.0 59.5±6.9**
BMI (kg/m
2) 31.3±5.2 31.7±5.2
Total cholesterol
(mmol/l)
4.9±1.0 5.6±1.1**
Total triacylglycerol
(mmol/l)
2.2±2.0 2.0±1.4*
HDL-cholesterol
(mmol/l)
1.2±0.4 1.3±0.4**
LDL-cholesterol
(mmol/l)
2.8±0.9 3.5±1.0**
Data shown are mean±SD, unless otherwise indicated
*p<0.05 vs participants on lipid lowering therapy
**p<0.001 vs participants on lipid lowering therapy
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potential for benefit on cardiovascular outcomes that the
present analysis demonstrates.
Strengths and weaknesses of the study This study is large,
involving the screening of 76,308 people in 334 general
practices in order to find the 3,057 people with screen-
detected diabetes who were randomised to different
approaches to care. A key element of the ADDITION trial
designisthattheinterventionisdeliveredinprimarycare.The
trial is a pragmatic evaluation of the magnitude of the costs
and benefits of screening and intensified treatment in this
real-world setting. This design has the advantage that one can
generalisefromthe resultsofthe trialtothe expectedoutcome
if and when the approach is more widely adopted. The
disadvantage is that it is much more difficult from a practical
perspective to undertake a trial embedded within everyday
primary care practice than it is in a specialist research
organisation. In the trial, a total of 334 general practices
participated and although reminder systems were established
to ensure that datasets were as complete as possible, there
is a higher degree of missing data than would be present
if the trial had been conducted in a more controlled
environment.
Comparison with other studies The level of CHD risk
estimated by the UKPDS risk engine in ADDITION trial
participants who had been detected by a stepwise process
of diabetes screening is comparable with that of diabetic
patients of a similar age who have been diagnosed
conventionally in routine clinical practice. In the analysis
by Song and Brown of CHD risk estimation in 700 British
patientswithprevalenttype2diabetes(meanage59.8years),
the mean (SD) 10 year CHD risk in men was 24.9% (SD
13.2), whereas it was 16.5% (SD 9.4) in women [30].
Although the risk estimator ranks risk well, it may result in
an underestimation of true risk. In a comparison of risk
estimated by the UKPDS risk engine or the Framingham
risk score compared with true risk, Guzder and colleagues
demonstrated that the Framingham risk score underesti-
mated coronary events in a population of people with
type 2 diabetes by 32%. At 13%, the degree of underesti-
mation by the UKPDS risk engine was lower [31]. As with
all other risk calculators, the computation of risk for CHD
by the UKPDS risk engine is heavily influenced by age and
sex, since these are dominant factors that determine absolute
risk levels. Thus in our study, by definition, estimated risk
is higher in men and in the older age groups. Compared
with the cohort of patients in the UKPDS study [4], the
participants recruited to the ADDITION study were older,
more obese, more hypertensive and had higher levels of
serum cholesterol.
Similar differences also exist between the ADDITION
study cohort and previous populations of people with
screen-detected type 2 diabetes. Overall, ADDITION study
participants are older, more obese and more hypertensive
than people with prevalent but undiagnosed diabetes in the
Ely [10] and Inter99 [9] studies. These differences between
our participants and previous studies of prevalent and
previously undiagnosed diabetes may be connected (1) with
our requirement for confirmation of the biochemical
diagnosis of diabetes on a different day, which was not a
characteristic of some previous epidemiological studies, or
(2) with the screening strategy employed by us, which used
risk scores that predict prevalent but undiagnosed diabetes.
Factors including age, BMI and presence of known
hypertension are part of these risk scores. Thus, through
their use as part of a process of stepwise screening, we may
have combined screening for diabetes with the selection of
individuals who are at higher cardiovascular risk. The only
subpopulation in the ADDITION study in whom universal
screening rather than a stepwise approach was used was
that of the Leicester centre. As 40% of the recruited people
with diabetes in Leicester were non-white, this approach is
still likely to lead to the selection of a population at higher
CHD risk [32]. We demonstrated between-country differ-
ences in the distribution of metabolic risk factors, which
were due in part to variations in approaches to screening,
variations in the prevalence of lifestyle behaviours (e.g.
cigarette smoking), and differences in the extent to which
risk factors such as blood pressure and lipids had already
been detected and adequately treated.
Interpretation of our findings A key criterion that deter-
mines whether a screening programme for any particular
condition should be considered is the availability of
evidence showing that earlier detection and treatment is
associated with improved outcomes. In the context of
diabetes, if people whose disease was detected by screening
were already receiving intensive treatment for CHD risk
factors apart from hyperglycaemia, diagnosis of their
diabetes should be unlikely to have a major impact on
CHD risk. Thus the observation made in this study that
people with screen-detected diabetes are at high CHD risk
and that this risk is potentially modifiable by intensification
of treatment could have a potentially critical impact. The
scope for intervention is considerable, since in addition to
untreated or insufficiently treated hyperglycaemia, hyper-
tension and hypercholesterolaemia, nearly one third of the
cohort were current smokers and almost all were over-
weight, high-lighting the potential for lifestyle intervention
in addition to intensified pharmacological therapy. The task
of determining whether such intensification of treatment is
possible in primary care and whether it will have the
1132 Diabetologia (2008) 51:1127–1134expected impact on reducing cardiovascular events is a key
goal of the 5 year follow-up of the ADDITION trial, which
will be complete in 2009.
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